Apel­lis’ Syfovre on the come­back trail from vas­culi­tis wor­ries af­ter $74M in ini­tial Q3 sales

Apel­lis Phar­ma­ceu­ti­cals’ eye drug Syfovre is on track for a re-ac­cel­er­at­ed launch af­ter a re­al world safe­ty scare, with the com­pa­ny an­nounc­ing pre­lim­i­nary US net sales of $74 mil­lion in the third quar­ter.

Syfovre won FDA ap­proval for ge­o­graph­ic at­ro­phy sec­ondary to wet age-re­lat­ed mac­u­lar de­gen­er­a­tion in Feb­ru­ary and launched in March. But its tra­jec­to­ry was soon be­set by un­ex­pect­ed re­al world events of in­traoc­u­lar in­flam­ma­tion and reti­nal vas­culi­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER